Association of the location and initial degree of malignant central airway stenosis with the risk of severe restenosis after interventional bronchoscopy

Table 1 Baseline characteristics of the study participants

Characteristics	Value
Age (y), (mean ± SD)	66.6 ± 8.2
Male, n (%)	214 (91.8)
Smoking, n (%)	166 (71.2)
Coexisting disease, n (%)
COPD	21 (9.0)
Hypertension	58 (24.9)
Diabetes	11 (4.7)
Dyspnea index, n (%)	13 (2.5)
0	42 (18.0)
1	9 (3.9)
2	27 (11.6)
3	30 (12.9)
4	125 (53.6)
Location of the lesion, n (%)
Trachea	34 (14.6)
Left main bronchus	75 (32.2)
Right main bronchus	78 (33.5)
Right intermediate bronchus	46 (19.7)
Initial degree of MCAS, (mean ± SD, %)	76.9 ± 23.9
Post-intervention residual stenosis, (mean ± SD, %)	28.4 ± 17.3
Histological types, n (%)
Lung adenocarcinoma	5 (2.1)
Lung squamous cell carcinoma	186 (79.8)
SCLC	17 (7.3)
Other*	25 (10.7)
Stent implantation, n (%)	56 (24.0)
Other treatments after intervention,* n (%)*
0	50 (21.5)
1	81 (34.8)
≥ 2	102 (43.8)
Severe restenosis, n (%)	92 (39.5)

COPD chronic obstructive pulmonary disease, MCAS malignant central airway stenosis, SCLC small-cell lung carcinoma
*Other histological types including adenoid cystic carcinoma, lymphoma, large cell neuroendocrine carcinoma, mesenchymal tumor, soft tissue sarcoma, and metastatic malignancies (esophageal cancer, gastric cancer, colorectal adenocarcinoma, and thyroid papillary carcinoma)
**Other treatments including radiotherapy, chemotherapy, molecule-targeted therapy, and immunotherapy. 0, patients didn’t receive any other treatment after therapeutic bronchoscopy; 1, patients received one other treatment after therapeutic bronchoscopy; ≥2, patients received at least two other treatments after therapeutic bronchoscopy

ISSN: 1471-2466